Calcitonin gene-related peptide and pain: a systematic review

Abstract

BackgroundCalcitonin gene-related peptide (CGRP) is widely distributed in nociceptive pathways in human peripheral and central nervous system and its receptors are also expressed in pain pathways. CGRP is involved in migraine pathophysiology but its role in non-headache pain has not been clarified.MethodsWe performed a systematic literature search on PubMed, Embase and ClinicalTrials.gov for articles on CGRP and non-headache pain covering human studies including experimental studies and randomized clinical trials.ResultsThe literature search identified 375 citations of which 50 contained relevant original data. An association between measured CGRP levels and somatic, visceral, neuropathic and inflammatory pain was found. In 13 out of 20 studies in somatic pain conditions, CGRP levels had a positive correlation with pain. Increased CGRP levels were reported in plasma, synovial and cerebrospinal fluid in subjects with musculoskeletal pain. A randomized clinical trial on monoclonal antibody, which selectively binds to and inhibits the activity of CGRP (galcanezumab) in patients with osteoarthritis knee pain, failed to demonstrate improvement of pain compared with placebo. No studies to date have investigated the efficacy of monoclonal antibodies against CGRP receptor in non-headache pain conditions.ConclusionThe present review revealed the association between measured CGRP levels and somatic, visceral, neuropathic and inflammatory pain. These data suggest that CGRP may act as a neuromodulator in non-headache pain conditions. However, more studies are needed to fully understand the role of CGRP in nociceptive processing and therapy of chronic pain.Electronic supplementary materialThe online version of this article (doi:10.1186/s10194-017-0741-2) contains supplementary material, which is available to authorized users.

A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch

“…The release of calcitonin gene–related peptide (CGRP) by sensory neurons is implicated in the pathophysiology of numerous pain disorders (18, 19). The classic nociceptive mediator prostaglandin E 2 (PGE 2 ) does not significantly alter CGRP release at 1 μM concentrations at neutral pH (20, 21); however, PGE 2 augments CGRP release evoked by low pH (which mimics an inflammatory state) or capsaicin (which activates ion channels involved in nociception) (20, 21), indicating DRG sensitization.…”

Pathophysiology of chronic pain in cerebral palsy: implications for pharmacological treatment and research

“…Both approaches have shown efficacy in clinical trials, but the receptor antagonists have been discontinued owing to liver toxicity . Intriguingly, CGRP levels in plasma, synovial, and cerebrospinal fluid and tissue biopsies are elevated and correlated to pain in individuals with degenerative disc disease and osteoarthritis . Thus, it has been proposed that CGRP may be a critical factor also in non‐migraine pain, but this remains to be defined.…”

Is Helicobacter Pylori Associated with a Migraine?

“…Additionally, our results recovered relationship between migraine and joint pains, this could be interpreted in the light of the CGRP induced synovitis, where it was found that CGRP contributes to transition from normal to persistent synovitis, and the progression from nociception to sensitization [39]. Also, CGRP may play a role in pain transmission in somatic pain conditions such as joint and muscular chronic pain [40].…”